Blogs

Stay informed with the latest trends, updates, and expert insights in quality assurance, regulatory affairs, and compliance. Our blogs are designed to keep you ahead in the ever-evolving world of healthcare and pharmaceuticals.

Visual Inspection 4.0: Machines That Never Miss a Defect (And Regulators Love It)

Visual Inspection 4.0: Machines That Never Miss a Defect (And Regulators Love It)

How to Survive a Hybrid GMP Inspection Without a Single Observation

How to Survive a Hybrid GMP Inspection Without a Single Observation

RMP 2.0: Digital Risk Management Plans Every Clinical Team Should Be Using

RMP 2.0: Digital Risk Management Plans Every Clinical Team Should Be Using

Biosimilars Under the Microscope: Post-Marketing Safety Shifts You Can’t Ignore

Biosimilars Under the Microscope: Post-Marketing Safety Shifts You Can’t Ignore

E2B(R3) Deadline April 2026: Is Your ICSR Submission Process FDA-Ready?

E2B(R3) Deadline April 2026: Is Your ICSR Submission Process FDA-Ready?

Annex 15 Revision: Key Impacts on Qualification and Validation for GDP Operators

Annex 15 Revision: Key Impacts on Qualification and Validation for GDP Operators

Navigating Dual MHRA/EMA Pharmacovigilance Obligations Post-Windsor Framework

Navigating Dual MHRA/EMA Pharmacovigilance Obligations Post-Windsor Framework

EU GMP Annex 22 (Artificial Intelligence): What GMP-Regulated Manufacturers Must Do Before the Effective Date

EU GMP Annex 22 (Artificial Intelligence): What GMP-Regulated Manufacturers Must Do Before the Effective Date

EU Pharma Package 2026: What It Means for GMP/GDP Operators Now

EU Pharma Package 2026: What It Means for GMP/GDP Operators Now

EudraVigilance Data Masking in ICSRs: Breaking Down the New GVP Module VI Addendum II

EudraVigilance Data Masking in ICSRs: Breaking Down the New GVP Module VI Addendum II

AI-Powered Signal Detection in 2026: Regulation, Use & Inspector Expectations

AI-Powered Signal Detection in 2026: Regulation, Use & Inspector Expectations

Third‑Party PV Subcontractors in the Crosshairs: How to Audit‑Proof Your Vendor Agreements

Third‑Party PV Subcontractors in the Crosshairs: How to Audit‑Proof Your Vendor Agreements

GVP Module IX Update in Q2 2026: What’s Changing and How to Prepare Now

GVP Module IX Update in Q2 2026: What’s Changing and How to Prepare Now

Signal Management Overhaul: How to Adapt Your SOPs After the Deletion of Article 21(2)

Signal Management Overhaul: How to Adapt Your SOPs After the Deletion of Article 21(2)

ESMP Compliance in 2026: EMA Pharmacovigilance & Shortage Reporting Essentials

ESMP Compliance in 2026: EMA Pharmacovigilance & Shortage Reporting Essentials

Unannounced FDA GMP Inspections: Readiness Guide for Foreign Facilities

Unannounced FDA GMP Inspections: Readiness Guide for Foreign Facilities

ICH E6(R3) & CRO Oversight: Risk-Based Vendor Audit Strategies

ICH E6(R3) & CRO Oversight: Risk-Based Vendor Audit Strategies

EU Pharmacovigilance Regulation 2025/1466: GvP Vendor Audit Essentials Before Feb 2026

EU Pharmacovigilance Regulation 2025/1466: GvP Vendor Audit Essentials Before Feb 2026

Why 87% of FDA Warning Letters Require External GMP Consultants

Why 87% of FDA Warning Letters Require External GMP Consultants

GDP Compliance Support for Pharmaceutical Wholesalers Under Inspection

GDP Compliance Support for Pharmaceutical Wholesalers Under Inspection

CAPA Remediation Support After Regulatory Inspections

CAPA Remediation Support After Regulatory Inspections

Vendor Audit Programs for GMP and PV: What Regulators Expect to See

Vendor Audit Programs for GMP and PV: What Regulators Expect to See

QPPV Services for MAHs: Defining Real Oversight in Outsourced PV Models

QPPV Services for MAHs: Defining Real Oversight in Outsourced PV Models

Do You Need a Pharmacovigilance Audit? Key Signs for UK Pharma Companies

Do You Need a Pharmacovigilance Audit? Key Signs for UK Pharma Companies

Internal vs External Audits in GMP and Pharmacovigilance: What UK Regulators Expect

Internal vs External Audits in GMP and Pharmacovigilance: What UK Regulators Expect

Top GMP and Pharmacovigilance Audit Findings and How to Avoid Them

Top GMP and Pharmacovigilance Audit Findings and How to Avoid Them

MHRA Inspection Readiness: A Detailed January Checklist for UK Pharma Companies

MHRA Inspection Readiness: A Detailed January Checklist for UK Pharma Companies

GMP, GDP and GVP Audits: What Pharma Companies Should Plan at the Start of the Year

GMP, GDP and GVP Audits: What Pharma Companies Should Plan at the Start of the Year

Top 5 Regulatory Changes Impacting Pharma in 2026 (And How to Prepare)

Top 5 Regulatory Changes Impacting Pharma in 2026 (And How to Prepare)

The Cost of Non-Compliance: Why Investing in Quality Systems Pays Off in 2026

The Cost of Non-Compliance: Why Investing in Quality Systems Pays Off in 2026

Post-Market Surveillance Evolution: What Changed in PV Regulations for 2026

Post-Market Surveillance Evolution: What Changed in PV Regulations for 2026

AI-Driven GMP Audits: Transforming Pharma Compliance in 2026

AI-Driven GMP Audits: Transforming Pharma Compliance in 2026

Risk-Based Auditing: How to Spot Problems Before They Become Crises

Risk-Based Auditing: How to Spot Problems Before They Become Crises

GxP Inspection Trends for 2026: What Health Authorities Are Targeting Now

GxP Inspection Trends for 2026: What Health Authorities Are Targeting Now

5 Critical Mistakes Companies Make During PV Inspections (And How to Avoid Them in 2026)

5 Critical Mistakes Companies Make During PV Inspections (And How to Avoid Them in 2026)

Why Your Pharmacovigilance System Master File Could Fail Your Next Inspection

Why Your Pharmacovigilance System Master File Could Fail Your Next Inspection

The Hidden Costs of Poor ICSR Case Processing: Why Quality Matters More Than Speed

The Hidden Costs of Poor ICSR Case Processing: Why Quality Matters More Than Speed

Real World Evidence RWE in Regulatory Submissions: FDA and EMA Acceptance Criteria

Real World Evidence RWE in Regulatory Submissions: FDA and EMA Acceptance Criteria

How to Prepare for an MHRA Inspection: Expert Tips from Quality and Vigilance

How to Prepare for an MHRA Inspection: Expert Tips from Quality and Vigilance

Brexit Impact on UK Pharmaceutical Regulations: What Has Changed in 2025

Brexit Impact on UK Pharmaceutical Regulations: What Has Changed in 2025

Diversity & Inclusion in Drug Safety: Ensuring PV Systems Monitor All Patient Groups Equitably

Diversity & Inclusion in Drug Safety: Ensuring PV Systems Monitor All Patient Groups Equitably

Patient-Generated Safety Data: Wearables, Social Media & Mobile Reporting – What Auditors Need to Know

Patient-Generated Safety Data: Wearables, Social Media & Mobile Reporting – What Auditors Need to Know

Strengthening Pharmacovigilance in Low- and Middle-Income Countries (LMICs)

Strengthening Pharmacovigilance in Low- and Middle-Income Countries (LMICs)

Preparing for the Next Generation of Regulation: How Upcoming Guidelines Will Shape Pharmacovigilance Audits

Preparing for the Next Generation of Regulation: How Upcoming Guidelines Will Shape Pharmacovigilance Audits

Pharmacovigilance for Advanced Therapies: Auditing Safety in Cell, Gene and Tissue Products

Pharmacovigilance for Advanced Therapies: Auditing Safety in Cell, Gene and Tissue Products

Ethical Considerations in Patient-Centric Pharmacovigilance: Auditing Consent, Privacy and Data Use in Digital Health

Ethical Considerations in Patient-Centric Pharmacovigilance: Auditing Consent, Privacy and Data Use in Digital Health

Getting Inspection-Ready for 2026: How to Prepare Your Pharmaceutical Site Now

Getting Inspection-Ready for 2026: How to Prepare Your Pharmaceutical Site Now

Pharmacovigilance in Rare Diseases and Orphan Drugs: Ensuring Safety in Challenging Therapeutic Areas

Pharmacovigilance in Rare Diseases and Orphan Drugs: Ensuring Safety in Challenging Therapeutic Areas

Pharmacovigilance for Medical Devices and IVDs: Ensuring Safety and Compliance

Pharmacovigilance for Medical Devices and IVDs: Ensuring Safety and Compliance

What Makes a Good Pharmacovigilance System Master File (PSMF)

What Makes a Good Pharmacovigilance System Master File (PSMF)

Pharmacovigilance Outsourcing: Benefits, Risks, and Selection Tips

Pharmacovigilance Outsourcing: Benefits, Risks, and Selection Tips

Newsletter Signup

Subscribe to our newsletter for the latest insights